-
Vanderbilt CTTC drives record innovation impact in FY25
Vanderbilt CTTC had an exceptional 2025 fiscal year, setting all-time records across multiple metrics while expanding the university's innovation impact. -
Vanderbilt-Discovered Compound Advances to Phase 1 Clinical Trial as a Promising New Treatment for Schizophrenia
Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia. -
Image
Letter from the Director, 2024
Research universities across the country have awakened to the critical importance of achieving impact through innovation. This is meaningfully affecting their campus cultures, delivering for their communities, and is important for society at large, as innovative advancements drive the economy,…